Policy and regulation stand in the way of NHS use of unlicensed eye injection drug with potential to save millions of pounds
Eye injection drugs recommended by NICE cost the NHS up to £ 447 million annually, but could be replaced by an unlicensed drug, bevacizumab, costing as much as ten times less. Use of the two licensed drugs, ranibizumab and aflibercept, has increased three-fold over the last five years, with some parts of England treating five times as many patients as others. (Source: University of Bristol news)
Source: University of Bristol news - November 1, 2017 Category: Universities & Medical Training Tags: Health, Research; Faculty of Health Sciences, Faculty of Health Sciences, Bristol Medical School, Faculty of Health Sciences, Population Health Sciences; Press Release Source Type: news
Ranibizumab Beats Laser for Diabetic Retinopathy Ranibizumab Beats Laser for Diabetic Retinopathy
New trial findings are challenging the standard of care for diabetic retinopathy and are opening the door to wider use of anti-vascular endothelial growth factor drugs.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 10, 2017 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Analysis Favors Aflibercept for Diabetic Macular Edema Analysis Favors Aflibercept for Diabetic Macular Edema
Aflibercept appears to be more effective than ranibizumab, with or without laser photocoagulation, in a new meta-analysis of treatments for diabetic macular edema.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 9, 2017 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Opthea touts data from wet-AMD trial
Opthea (ASX:OPT) touted additional data today from the Phase I/IIa trial of its wet age-related macular degeneration therapy, OPT-302.
The 50-patient Phase I/IIa trial recruited participants who were either treatment-naive or previously treated with an intravitreal anti-VEGF therapy. Researchers evaluated OPT-302 as a monotherapy and in combination with Lucentis (ranibizumab).
Get the full story at our sister site, Drug Delivery Business News.
The post Opthea touts data from wet-AMD trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 15, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Opthea Source Type: news
Aflibercept May Be Effective for Resistant Exudative AMD Aflibercept May Be Effective for Resistant Exudative AMD
Aflibercept appears to improve outcomes in patients with exudative age-related macular degeneration (AMD) resistant to treatment with ranibizumab or bevacizumab, researchers from Norway report.Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - June 14, 2017 Category: Opthalmology Tags: Ophthalmology News Source Type: news
Minimal Differences Between Anti-VEGF Drugs on IOP Over Time Minimal Differences Between Anti-VEGF Drugs on IOP Over Time
Patients on anti-VEGF therapy may have a small decrease in intraocular pressure (IOP) over time, but with minimal differences between aflibercept, ranibizumab, and bevacizumab, a new large study suggests.Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - June 1, 2017 Category: Opthalmology Tags: Ophthalmology News Source Type: news
FDA approves Roche ’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States
Roche today announced that the US Food and Drug Administration (FDA) approved Lucentis ® (ranibizumab injection) 0.3 mg for the monthly treatment of withal forms of diabetic retinopathy. (Source: Roche Investor Update)
Source: Roche Investor Update - April 18, 2017 Category: Pharmaceuticals Source Type: news
FDA approves Roche ’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States
Roche today announced that the US Food and Drug Administration (FDA) approved Lucentis ® (ranibizumab injection) 0.3 mg for the monthly treatment of withal forms of diabetic retinopathy. (Source: Roche Media News)
Source: Roche Media News - April 18, 2017 Category: Pharmaceuticals Source Type: news
FDA OKs Ranibizumab for All Forms of Diabetic Retinopathy FDA OKs Ranibizumab for All Forms of Diabetic Retinopathy
The VEFG inhibitor had been approved just for diabetic retinopathy accompanied by diabetic macular edema, in addition to other eye disorders.FDA Approvals (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 18, 2017 Category: Endocrinology Tags: Ophthalmology News Alert Source Type: news
FDA Approves Genentech ’s Lucentis (ranibizumab) for all Forms of Diabetic Retinopathy
South San Francisco, CA -- April 17, 2017 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Lucentis ® (ranibizumab injection) 0.3 mg for the monthly... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 17, 2017 Category: Drugs & Pharmacology Source Type: news
Cardiovascular Safety of Ranibizumab for Diabetic Macular Edema Still Unclear Cardiovascular Safety of Ranibizumab for Diabetic Macular Edema Still Unclear
Uncertainty lingers about the cardiovascular safety of intravitreal ranibizumab injections for diabetic macular edema, a pooled analysis of clinical trials shows.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 12, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Opthea gets positive feedback from European regulatory groups for wet-AMD injection
Opthea (ASX:OPT) said today that it received positive feedback from meetings with the U.K.’s Medicines and Healthcare Products Regulatory Agency and Sweden’s Medical Products Agency over its OPT-302 therapy for the treatment of wet age-related macular degeneration.
The Australia-based company’s OPT-302 therapy consists of a soluble form of vascular endothelial growth factor receptor 3 that blocks the activity of 2 proteins that cause blood vessels to grow and leak. It is being evaluated in a phase 1/2 clinical trial in patients with wet AMD as a monotherapy and with ranibizumab, delivered as monthly intravitreal inje...
Source: Mass Device - March 20, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Optical/Ophthalmic Regulatory/Clearance Wall Street Beat Opthea Source Type: news
Researchers develop micropump for patients with glaucoma
Researchers from the University of Southern California’s Roski Eye Institute developed a micropump that can be implanted directly into the eye and deliver a predetermined dose of the diabetic macular edema drug ranibizumab.
Current treatments for glaucoma are traditionally delivered using eye drops. But studies show that some patients stop taking their prescription glaucoma eye drops after 1 year, according to the team of researchers. Patients can be uncomfortable using the eye drops or they forget to consistently take their prescribed medication.
Get the full story at our sister site, Drug Delivery Business News.
...
Source: Mass Device - March 3, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Optical/Ophthalmic Research & Development Replenish Inc Source Type: news
Lucentis (Ranibizumab Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 27, 2017 Category: Drugs & Pharmacology Source Type: news
Baseline Characteristics and Outcomes of Ranibizumab for DME Baseline Characteristics and Outcomes of Ranibizumab for DME
Data from this study provides insight into the patient characteristics and visual outcomes among those treated with ranibizumab injections for DME.The British Journal of Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 13, 2017 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news
